scPharmaceuticals (NASDAQ:SCPH) Lowered to Hold Rating by Maxim Group

Key Points

• Maxim Group has reiterated its "hold" rating for scPharmaceuticals (NASDAQ:SCPH), while Wall Street Zen has upgraded it from "sell" to "hold."
• scPharmaceuticals experienced a 13.7% stock increase recently, reaching $5.5150 with significant trading volume of 16,468,756 shares.
• In its latest earnings report, scPharmaceuticals reported an EPS of ($0.34), missing estimates, but revenues of $16.04 million exceeded expectations.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating in a research note issued to investors on Monday, Marketbeat.com reports.

Separately, Wall Street Zen upgraded scPharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $12.00.

scPharmaceuticals Stock Performance

SCPH traded up $0.01 during trading hours on Monday, hitting $5.53. 751,485 shares of the stock were exchanged, compared to its average volume of 545,245. The stock has a 50-day simple moving average of $4.68 and a 200-day simple moving average of $3.61. scPharmaceuticals has a 12 month low of $1.94 and a 12 month high of $6.28. The stock has a market cap of $294.47 million, a price-to-earnings ratio of -3.05 and a beta of 0.40. The company has a debt-to-equity ratio of 3.86, a current ratio of 3.85 and a quick ratio of 3.14.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The business had revenue of $16.04 million for the quarter, compared to the consensus estimate of $15.41 million. scPharmaceuticals had a negative net margin of 183.55% and a negative return on equity of 1,647.86%. Analysts anticipate that scPharmaceuticals will post -1.53 earnings per share for the current year.

Institutional Investors Weigh In On scPharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of SCPH. Captrust Financial Advisors lifted its stake in scPharmaceuticals by 9.0% during the second quarter. Captrust Financial Advisors now owns 43,746 shares of the company's stock valued at $167,000 after buying an additional 3,621 shares in the last quarter. Balanced Rock Investment Advisors LLC lifted its stake in scPharmaceuticals by 27.8% in the second quarter. Balanced Rock Investment Advisors LLC now owns 90,968 shares of the company's stock valued at $347,000 after acquiring an additional 19,768 shares during the last quarter. Pale Fire Capital SE bought a new stake in scPharmaceuticals in the second quarter worth $218,000. Walleye Capital LLC bought a new stake in shares of scPharmaceuticals during the 2nd quarter worth about $43,000. Finally, Lido Advisors LLC boosted its position in scPharmaceuticals by 14.6% during the second quarter. Lido Advisors LLC now owns 27,500 shares of the company's stock worth $105,000 after purchasing an additional 3,500 shares during the period. 89.52% of the stock is owned by institutional investors and hedge funds.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.